CA2286592A1 - Composes de 4-aminopyridol[2,3-d]pyrimidine a trisubstitution 5,6,7 - Google Patents

Composes de 4-aminopyridol[2,3-d]pyrimidine a trisubstitution 5,6,7 Download PDF

Info

Publication number
CA2286592A1
CA2286592A1 CA002286592A CA2286592A CA2286592A1 CA 2286592 A1 CA2286592 A1 CA 2286592A1 CA 002286592 A CA002286592 A CA 002286592A CA 2286592 A CA2286592 A CA 2286592A CA 2286592 A1 CA2286592 A1 CA 2286592A1
Authority
CA
Canada
Prior art keywords
phenyl
amino
pyrido
pyrimidine
formula
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002286592A
Other languages
English (en)
Inventor
Shripad S. Bhagwat
Richard J. Perner
Yu Gui Gu
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Abbott Laboratories
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2286592A1 publication Critical patent/CA2286592A1/fr
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Pain & Pain Management (AREA)
  • Diabetes (AREA)
  • Cardiology (AREA)
  • Rheumatology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Transplantation (AREA)
  • Emergency Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Obesity (AREA)
  • Oncology (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Vascular Medicine (AREA)
  • Communicable Diseases (AREA)
  • Psychiatry (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

Un composé représenté par la formule générale (II) où R?1¿, R?2¿, R?3¿, R?4¿ et R?5¿ sont conformes à la description qui en est donnée dans la demande. Un procédé permettant d'inhiber l'adénosine kinase par administration d'un tel composé. Une composition pharmaceutique comprenant une quantité thérapeutiquement suffisante d'un tel composé en association avec un excipient pharmaceutiquement acceptable. Un traitement de l'ischémie cérébrale, de l'épilepsie, de la douleur, de la nociception, de l'inflammation, de la septicémie, dans le cas d'un mammifère nécessitant un tel traitement, lequel traitement consiste en l'administration, au mammifère considéré, d'une quantité thérapeutiquement suffisante d'un tel composé. Un procédé de préparation d'un tel composé.
CA002286592A 1997-04-16 1998-04-13 Composes de 4-aminopyridol[2,3-d]pyrimidine a trisubstitution 5,6,7 Abandoned CA2286592A1 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US84348497A 1997-04-16 1997-04-16
US08/843,484 1997-04-16
PCT/US1998/007201 WO1998046604A1 (fr) 1997-04-16 1998-04-13 Composes de 4-aminopyridol[2,3-d]pyrimidine a trisubstitution 5,6,7

Publications (1)

Publication Number Publication Date
CA2286592A1 true CA2286592A1 (fr) 1998-10-22

Family

ID=25290123

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002286592A Abandoned CA2286592A1 (fr) 1997-04-16 1998-04-13 Composes de 4-aminopyridol[2,3-d]pyrimidine a trisubstitution 5,6,7

Country Status (19)

Country Link
EP (1) EP0975633A1 (fr)
JP (1) JP2001520654A (fr)
KR (1) KR20010006462A (fr)
CN (1) CN1252069A (fr)
AR (1) AR012437A1 (fr)
AU (1) AU741033B2 (fr)
BG (1) BG103853A (fr)
BR (1) BR9809056A (fr)
CA (1) CA2286592A1 (fr)
CO (1) CO4940470A1 (fr)
HU (1) HUP0001443A3 (fr)
IL (1) IL131617A0 (fr)
NO (1) NO995035L (fr)
NZ (1) NZ337125A (fr)
PL (1) PL336265A1 (fr)
SK (1) SK140099A3 (fr)
TR (1) TR199902550T2 (fr)
WO (1) WO1998046604A1 (fr)
ZA (1) ZA983175B (fr)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001057040A1 (fr) * 2000-02-03 2001-08-09 Abbott Laboratories Composes de 4-aminopyrido[2,3-d]pyrimidine a disubstitution en position 6,7
JP4064818B2 (ja) 2001-02-12 2008-03-19 エフ．ホフマン−ラ ロシュ アーゲー ６−置換ピリド−ピリミジン類
CN107744520A (zh) * 2017-10-25 2018-03-02 南京多宝生物科技有限公司 嘧啶类化合物在制备促进小肠蠕动药物中的应用
CN112209924B (zh) * 2019-07-09 2022-04-05 中国科学院天津工业生物技术研究所 选择性腺苷a1受体拮抗剂

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB774094A (en) * 1953-01-02 1957-05-08 Wellcome Found Improvements in or relating to pyrimidine compounds
IL112249A (en) * 1994-01-25 2001-11-25 Warner Lambert Co Pharmaceutical compositions containing di and tricyclic pyrimidine derivatives for inhibiting tyrosine kinases of the epidermal growth factor receptor family and some new such compounds

Also Published As

Publication number Publication date
HUP0001443A3 (en) 2001-01-29
CN1252069A (zh) 2000-05-03
TR199902550T2 (xx) 2000-04-21
AU741033B2 (en) 2001-11-22
BG103853A (en) 2000-06-30
EP0975633A1 (fr) 2000-02-02
BR9809056A (pt) 2000-08-01
CO4940470A1 (es) 2000-07-24
JP2001520654A (ja) 2001-10-30
NO995035L (no) 1999-12-15
PL336265A1 (en) 2000-06-19
HUP0001443A2 (hu) 2000-10-28
IL131617A0 (en) 2001-01-28
KR20010006462A (ko) 2001-01-26
SK140099A3 (en) 2000-05-16
AR012437A1 (es) 2000-10-18
AU7108098A (en) 1998-11-11
NO995035D0 (no) 1999-10-15
ZA983175B (en) 1998-10-21
NZ337125A (en) 2001-06-29
WO1998046604A1 (fr) 1998-10-22

Similar Documents

Publication Publication Date Title
US5665721A (en) Heterocyclic substituted cyclopentane compounds
EP2086981B1 (fr) Composés destinés à inhiber la progression mitotique
WO2000023444A1 (fr) Composes de 4-aminopyrido[2,3-d]pyrimidine a disubstitution 5,7
KR20080080584A (ko) ｃ-Ｍｅｔ의 억제제 및 이의 용도
WO2002066480A2 (fr) 2-arylamino-pyrimidines pour le traitement de troubles associes a gsk3
JP2014513078A (ja) パーキンソン病の治療方法及び治療用組成物
WO1998046605A1 (fr) Composes de 4-aminopyrido[2,3-d]pyrimidine 5,7-disubstitues et leur utilisation comme inhibiteurs de l'adenosine kinase
ES2372320T3 (es) Compuestos útiles como inhibidores de proteínas quinasas.
JP2011518168A (ja) ホスファチジルイノシトール３−キナーゼの阻害薬
WO2005058315A1 (fr) Nouveaux composes heterocycliques utilises comme inhibiteurs et presentant une activite anti-hbv
WO2001057040A1 (fr) Composes de 4-aminopyrido[2,3-d]pyrimidine a disubstitution en position 6,7
AU744528B2 (en) 6,7-disubstituted-4-aminopyrido(2,3-d)pyrimidine compounds
US6030969A (en) 5,6,7-trisubstituted-4-aminopyrido[2,3-D] pyrimidine compounds
CA2286592A1 (fr) Composes de 4-aminopyridol[2,3-d]pyrimidine a trisubstitution 5,6,7
JP2013506691A (ja) ホスファチジルイノシトール３−キナーゼのピラゾール阻害薬
MXPA99009512A (en) 5,6,7-trisubstituted-4-aminopyridol[2,3-d]pyrimidine compounds
CZ350899A3 (cs) 5,6,7-trisubstituované-4-aminopyrido-[2,3- D]pyrimidinové sloučeniny
CZ360199A3 (cs) Sloučeniny 6,7-disubstituovaného-4- aminopyrido [2,3-dJ pyrimidinu
CZ339399A3 (cs) 5,7-Disubstituované 4-aminopyrido[2.3- D]pyrimidinové sloučeniny a jejich použití jako inhibitorů adenosin kinasy
AU2002232346A1 (en) 2-arylamino-pyrimidines for the treatment of GSK3-related disorders

Legal Events

Date Code Title Description
FZDE Discontinued